Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will participate in a presentation and fireside chat at upcoming investor conferences:
Piper Sandler 34th Annual Healthcare Conference
Format: Presentation
Date: Tuesday, November 29, 2022
Time: 8:30 AM – 8:50 AM ET
5th Annual Evercore ISI HealthCONx Conference
Format: Fireside chat (virtual)
Date: Tuesday, November 29, 2022
Time: 1:50 PM – 2:10 PM ET
About Boundless Bio
Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of a new class of drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.
For more information, visit www.boundlessbio.com.
Follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005046/en/
Contacts
James Lee
Director of Business Development
Boundless Bio
jlee@boundlessbio.com
